Dasatinib is the generic version of Sprycel® tablets, a medication widely used for treating Ph+, chronic myeloid leukemia (CML) and Ph+ ALL ...

Zydus Lifesciences shares rose 7% following USFDA's final approval to market Dasatinib tablets across multiple strengths. The drug, a generic version of Sprycel tablets, is set to be produced at Zydus ...

The rise in Biocon share price came after the company announced that its wholly-owned subsidiary, Biocon Pharma, has received final approvals for Lenalidomide capsules and Dasatinib tabs from USFDA ...

Dasatinib is prescribed for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in adults.

The company launched ANVIMO (Letermovir), a breakthrough in the prevention of Cytomegalovirus (CMV) infection for haematopoietic stem cell transplant (HSCT) and kidney transplant patients. ANVIMO will ...

A pilot study indicates that senolytic medications, Dasatinib and Quercetin, may improve cognitive function in older adults at risk for Alzheimer's disease by targeting senescent cells.

With annual US sales of $1.81 billion, as per IQVIA MAT data (January 2025), this approval marks a significant milestone for Zydus. The company will manufacture Dasatinib at its Ahmedabad SEZ facility ...

Zydus Lifesciences. The pharmaceutical company has obtained final approval from the United States Food and Drug ...

A new pilot study known as STAMINA (Senolytics To Alleviate Mobility Issues and Neurological Impairments in Aging), that focused on the effects of senolytic medications, Dasatinib and Quercetin ...

The company's subsidiary, Biocon Pharma, has received USFDA approvals for Lenalidomide capsules and Dasatinib tablets, and ...